164 related articles for article (PubMed ID: 31895608)
1. Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
Nossiter J; Sujenthiran A; Cowling TE; Parry MG; Charman SC; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
J Clin Oncol; 2020 Mar; 38(7):744-752. PubMed ID: 31895608
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes.
Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
Downing A; Wright P; Hounsome L; Selby P; Wilding S; Watson E; Wagland R; Kind P; Donnelly DW; Butcher H; Catto JWF; Cross W; Mason M; Sharp L; Weller D; Velikova G; McCaughan E; Mottram R; Allen M; Kearney T; McSorley O; Huws DW; Brewster DH; McNair E; Gavin A; Glaser AW
Lancet Oncol; 2019 Mar; 20(3):436-447. PubMed ID: 30713036
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand.
Pryor DI; Martin JM; Millar JL; Day H; Ong WL; Skala M; FitzGerald LM; Hindson B; Higgs B; O'Callaghan ME; Syed F; Hayden AJ; Turner SL; Papa N
JAMA Netw Open; 2021 Nov; 4(11):e2129647. PubMed ID: 34724555
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study.
Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Radiother Oncol; 2021 Feb; 155():48-55. PubMed ID: 33075390
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
[TBL] [Abstract][Full Text] [Related]
9. Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort.
Wallis CJD; Huang LC; Zhao Z; Penson DF; Koyama T; Conwill R; Tallman JE; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Barocas DA; Hoffman KE
Urol Oncol; 2022 Feb; 40(2):56.e1-56.e8. PubMed ID: 34154899
[TBL] [Abstract][Full Text] [Related]
10. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
Tyson MD; Koyama T; Lee D; Hoffman KE; Resnick MJ; Wu XC; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Paddock LE; Stroup A; Chen V; Conwill R; McCollum D; Penson DF; Barocas DA
Eur Urol; 2018 Jul; 74(1):26-33. PubMed ID: 29501451
[TBL] [Abstract][Full Text] [Related]
11. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom.
Donnelly DW; Gavin A; Downing A; Hounsome L; Kearney T; McNair E; Allan D; Huws DW; Wright P; Selby PJ; Kind P; Watson E; Wagland R; Wilding S; Butcher H; Mottram R; Allen M; McSorley O; Sharp L; Mason MD; Cross WR; Catto JWF; Glaser AW
Eur Urol; 2019 Aug; 76(2):228-237. PubMed ID: 31060822
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
14. Conventional Versus Hypofractionated Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24-Month Patient-Reported Outcomes of the Randomized Phase 2 CHIRP Trial.
Yang F; Ghosh S; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Field C; Fallone G; Murtha A
Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):99-107. PubMed ID: 35537578
[TBL] [Abstract][Full Text] [Related]
15. Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: A population-based patient-reported outcome study.
Wilding S; Downing A; Selby P; Cross W; Wright P; Watson EK; Wagland R; Kind P; Donnelly DW; Hounsome L; Mottram R; Allen M; Kearney T; Butcher H; Gavin A; Glaser A
Psychooncology; 2020 May; 29(5):886-893. PubMed ID: 32065691
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
[TBL] [Abstract][Full Text] [Related]
17. Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
Movsas B; Rodgers JP; Elshaikh MA; Martinez AA; Morton GC; Krauss DJ; Yan D; Citrin DE; Hershatter BW; Michalski JM; Ellis RJ; Kavadi VS; Gore EM; Gustafson GS; Schulz CA; Velker VM; Olson AC; Cury FL; Papagikos MA; Karrison TG; Sandler HM; Bruner DW
J Clin Oncol; 2023 Jun; 41(17):3217-3224. PubMed ID: 37104723
[TBL] [Abstract][Full Text] [Related]
18. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study.
Mazariego CG; Egger S; King MT; Juraskova I; Woo H; Berry M; Armstrong BK; Smith DP
BMJ; 2020 Oct; 371():m3503. PubMed ID: 33028540
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
20. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
